Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07838220
PHASE1

A Study of IBI3016 in Japanese Participants

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

View on ClinicalTrials.gov

Summary

A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.

Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous Administration of IBI3016 in Japanese Participants With Mild to Moderate Hypertension

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-08-01

Completion Date

2027-11-05

Last Updated

2026-09-24

Healthy Volunteers

No

Conditions

Interventions

DRUG

IBI3016 Dose 4

single doses of IBI3016 administered by subcutaneous injection

DRUG

IBI3016 Dose 3

single doses of IBI3016 administered by subcutaneous injection

DRUG

IBI3016 Dose 2

single doses of IBI3016 administered by subcutaneous injection

DRUG

IBI3016 Dose 1

single doses of IBI3016 administered by subcutaneous injection

DRUG

Placebo

single doses of IBI3016 administered by subcutaneous injection

Locations (1)

Medical Corporation Heishinkai OPHAC Hospital

Osaka, Japan